In an era of drug development that’s produced seeming miracles like gene editing and cancer immunotherapy, the business of “injectables” may come across as quaint. But there’s nothing boring about coming up with new ways of mixing and administering therapies in a way that helps patients in novel ways. And there’s certainly nothing boring about a 36% return on shareholder investment in 2018 alone. Eagle Pharmaceuticals is a standout among its specialty pharmaceutical peers for investors, no matter how bread-and-butter its aspirations may seem.
Looking for leads, investment insights, or competitive intelligence?